AbCellera Biologics Inc. (ABCL)

NMS – Real vaqt narxi. Valyuta: USD

4.95

-0.30 (-5.71%)

Yopilishda: May 12, 2026, 4:00 PM EDT

4.93

-0.02 (-0.40%)

Bozor oldidan: May 13, 2026, 4:01 AM EDT

12.05.2026

AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript

11.05.2026

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics NASDAQ: ABCL said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years.

11.05.2026

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.15 per share a year ago.

11.05.2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635.

07.05.2026

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in May and June 2026.

20.04.2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.

01.04.2026

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635.

20.04.2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.

24.02.2026

AbCellera Reports Full Year 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.

12.01.2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause.

AbCellera Biologics Inc. (ABCL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Videolar

No Data

Press-relizlar

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Reports Full Year 2025 Business Results

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Videolar

No Data

Press-relizlar

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Reports Full Year 2025 Business Results

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Search stocks

AbCellera Biologics Inc. (ABCL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Videolar

No Data

Press-relizlar

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Reports Full Year 2025 Business Results

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Videolar

No Data

Press-relizlar

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Reports Full Year 2025 Business Results

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause